A systemic autoimmune disease and distinct subset of the idiopathic inflammatory myopathies, defined serologically by circulating autoantibodies against one of the cytoplasmic aminoacyl-tRNA synthetases (most commonly anti-Jo-1 / anti-histidyl-tRNA synthetase; also anti-PL-7, anti-PL-12, anti-EJ, anti-OJ, anti-KS). It is dominated by a constellation of interstitial lung disease (often the prognosis-determining feature), inflammatory myositis, and inflammatory (usually non-erosive) arthritis, frequently accompanied by mechanic's hands, Raynaud phenomenon, and unexplained fever. The ILD-predominant, antibody-defined phenotype distinguishes it from classic polymyositis and dermatomyositis. It is multifactorial/autoimmune (HLA-associated), not Mendelian.
Ask a research question about Antisynthetase Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
Conditions with similar clinical presentations that must be differentiated from Antisynthetase Syndrome:
name: Antisynthetase Syndrome
creation_date: "2026-06-29T00:00:00Z"
category: Complex
disease_term:
preferred_term: Antisynthetase Syndrome
term:
id: MONDO:0019344
label: antisynthetase syndrome
description: >-
A systemic autoimmune disease and distinct subset of the idiopathic inflammatory
myopathies, defined serologically by circulating autoantibodies against one of the
cytoplasmic aminoacyl-tRNA synthetases (most commonly anti-Jo-1 / anti-histidyl-tRNA
synthetase; also anti-PL-7, anti-PL-12, anti-EJ, anti-OJ, anti-KS). It is dominated by a
constellation of interstitial lung disease (often the prognosis-determining feature),
inflammatory myositis, and inflammatory (usually non-erosive) arthritis, frequently
accompanied by mechanic's hands, Raynaud phenomenon, and unexplained fever. The
ILD-predominant, antibody-defined phenotype distinguishes it from classic polymyositis
and dermatomyositis. It is multifactorial/autoimmune (HLA-associated), not Mendelian.
synonyms:
- Anti-synthetase syndrome
- Anti-aminoacyl-tRNA synthetase syndrome
- Anti-Jo-1 syndrome
- ASyS
- ASSD
parents:
- Autoimmune Disease
- Inflammatory Myopathy
pathophysiology:
- name: Loss of Tolerance to Aminoacyl-tRNA Synthetases
description: >-
The defining upstream event is breakdown of immune tolerance to one of the cytoplasmic
aminoacyl-tRNA synthetase (aaRS) enzymes, generating circulating anti-aaRS
autoantibodies. The autoantibodies are believed to be mechanistically central rather
than bystanders, and their titers track disease activity. The aaRS enzymes are
housekeeping enzymes whose native role is tRNA aminoacylation.
role: trigger
molecular_functions:
- preferred_term: Aminoacyl-tRNA ligase activity (autoantigen native function)
term:
id: GO:0004812
label: aminoacyl-tRNA ligase activity
evidence:
- reference: PMID:36280495
reference_title: "Mechanistic perspectives on anti-aminoacyl-tRNA synthetase syndrome."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Antisynthetase syndrome (ASSD) is an autoimmune disease characterized by circulating
autoantibodies against one of eight aminoacyl-tRNA synthetases
explanation: >-
Establishes that the disease is defined by autoantibodies against the aaRS enzymes,
the serological hallmark and upstream immune lesion.
downstream:
- target: Tissue-Specific Secretion of Aminoacyl-tRNA Synthetases
causal_link_type: DIRECT
- name: Tissue-Specific Secretion of Aminoacyl-tRNA Synthetases
description: >-
Damaged or regenerating muscle and inflamed lung secrete certain aaRS enzymes
extracellularly; this tissue-specific secretion is proposed as a key determinant of
which aaRS becomes an autoantigen, exposing the enzyme to the immune system outside its
normal cytoplasmic compartment.
cell_types:
- preferred_term: Skeletal muscle cell
term:
id: CL:0000188
label: cell of skeletal muscle
- preferred_term: Alveolar macrophage
term:
id: CL:0000583
label: alveolar macrophage
molecular_functions:
- preferred_term: Aminoacyl-tRNA ligase activity (secreted autoantigen)
term:
id: GO:0004812
label: aminoacyl-tRNA ligase activity
evidence:
- reference: PMID:36280495
reference_title: "Mechanistic perspectives on anti-aminoacyl-tRNA synthetase syndrome."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
we propose that ASSD pathogenesis involves the tissue-specific secretion of aaRSs
explanation: >-
Supports extracellular, tissue-specific secretion of aaRS enzymes as a proximal step
that makes the housekeeping enzyme available as an autoantigen.
downstream:
- target: tRNA-Triggered Toll-Like Receptor and Interferon Amplification
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- >-
Secreted aaRS is taken up and presented on MHC class II to aaRS-specific CD4+ T cells,
driving B-cell help and class-switched anti-aaRS antibody production; antibody binds
aaRS together with bound tRNA, forming immune complexes.
- name: tRNA-Triggered Toll-Like Receptor and Interferon Amplification
description: >-
Anti-aaRS antibodies bind the synthetase together with bound tRNA or tRNA fragments,
forming immune complexes that are internalized into endosomes where the nucleic-acid
cargo engages Toll-like receptor signaling and drives type I interferon release - a
self-amplifying innate-plus-adaptive loop that perpetuates autoantibody production and
tissue inflammation.
cell_types:
- preferred_term: Dendritic cell
term:
id: CL:0000451
label: dendritic cell
- preferred_term: Monocyte
term:
id: CL:0000576
label: monocyte
biological_processes:
- preferred_term: Toll-like receptor signaling pathway
term:
id: GO:0002224
label: toll-like receptor signaling pathway
modifier: INCREASED
- preferred_term: Type I interferon production
term:
id: GO:0032606
label: type I interferon production
modifier: INCREASED
evidence:
- reference: PMID:36280495
reference_title: "Mechanistic perspectives on anti-aminoacyl-tRNA synthetase syndrome."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
extracellular tRNAs or tRNA fragments and their ability to engage Toll-like receptor
signaling may be important disease factors
explanation: >-
Supports tRNA-driven Toll-like receptor engagement as an innate-immune amplification
mechanism in disease pathogenesis.
downstream:
- target: Autoantibody and Cytotoxic Immune Effector Production
causal_link_type: DIRECT
- name: Autoantibody and Cytotoxic Immune Effector Production
description: >-
aaRS-specific CD4+ T-cell help drives B cells and plasma cells to produce class-switched
anti-aaRS autoantibodies, while cytotoxic effector cells are recruited; the adaptive
response targets aaRS-expressing or aaRS-secreting tissues (lung, muscle, joint).
cell_types:
- preferred_term: CD4+ T cell
term:
id: CL:0000624
label: CD4-positive, alpha-beta T cell
- preferred_term: B cell
term:
id: CL:0000236
label: B cell
- preferred_term: Plasma cell
term:
id: CL:0000786
label: plasma cell
biological_processes:
- preferred_term: Immunoglobulin production
term:
id: GO:0002377
label: immunoglobulin production
modifier: INCREASED
- preferred_term: Adaptive immune response
term:
id: GO:0002250
label: adaptive immune response
evidence:
- reference: PMID:36280495
reference_title: "Mechanistic perspectives on anti-aminoacyl-tRNA synthetase syndrome."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
these autoantibodies are believed to play critical roles in
ASSD pathogenesis
explanation: >-
Supports the central pathogenic role of the produced anti-aaRS autoantibodies in
driving tissue-targeted disease.
downstream:
- target: Immune-Mediated Alveolar Injury and Interstitial Lung Disease
causal_link_type: DIRECT
- target: Immune-Mediated Myofiber Injury
causal_link_type: DIRECT
- name: Immune-Mediated Alveolar Injury and Interstitial Lung Disease
description: >-
Immune effectors and interferon programs injure the alveolar interstitium, producing
interstitial lung inflammation that can progress to fibrosis (NSIP > organizing
pneumonia > UIP patterns). ILD frequently predominates at presentation and is the
principal driver of morbidity and mortality.
cell_types:
- preferred_term: Type II pneumocyte
term:
id: CL:0002063
label: pulmonary alveolar type 2 cell
- preferred_term: Pulmonary interstitial fibroblast
term:
id: CL:0000057
label: fibroblast
biological_processes:
- preferred_term: Inflammatory response
term:
id: GO:0006954
label: inflammatory response
modifier: INCREASED
evidence:
- reference: PMID:27594777
reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The ILD in anti-synthetase syndrome patients is often severe and rapidly progressive,
causing much of the increased morbidity and mortality associated with anti-synthetase
syndrome as compared to the other IIMs
explanation: >-
Supports interstitial lung disease as the dominant, prognosis-determining tissue
injury in the syndrome.
- name: Immune-Mediated Myofiber Injury
description: >-
Skeletal myofibers undergo immune-mediated injury with characteristic perimysial
fragmentation, perifascicular necrosis, and aberrant sarcolemmal MHC class I
upregulation, producing inflammatory myositis with proximal muscle weakness and
elevated muscle enzymes.
cell_types:
- preferred_term: Skeletal muscle cell
term:
id: CL:0000188
label: cell of skeletal muscle
- preferred_term: CD8+ cytotoxic T cell
term:
id: CL:0000625
label: CD8-positive, alpha-beta T cell
biological_processes:
- preferred_term: MHC class I antigen processing and presentation
term:
id: GO:0002474
label: antigen processing and presentation of peptide antigen via MHC class I
modifier: INCREASED
evidence:
- reference: PMID:36280495
reference_title: "Mechanistic perspectives on anti-aminoacyl-tRNA synthetase syndrome."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Although these autoantibodies are believed to play critical roles in
ASSD pathogenesis, the nature of their roles remains unclear.
explanation: >-
Supports the autoantibody-centered immune mechanism underlying tissue (including
muscle) injury, while flagging residual mechanistic uncertainty.
phenotypes:
- name: Interstitial Lung Disease
category: Respiratory
frequency: VERY_FREQUENT
description: >-
The dominant organ manifestation; NSIP is the most common pattern, followed by
organizing pneumonia and UIP. Often predominates at presentation and may be rapidly
progressive. Prevalence ~86% in a 203-patient cohort.
phenotype_term:
preferred_term: Interstitial lung disease
term:
id: HP:0006515
label: Interstitial pneumonitis
clinical_course: PROGRESSIVE
evidence:
- reference: PMID:27594777
reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In a 2013 study of 203 anti-synthetase syndrome patients, the prevalence of ILD was
86%, more common than the prevalence of myositis (73%) or arthralgia/arthritis (60%)
explanation: >-
Supports both the association and a very-frequent (>80%) frequency band for ILD in
antisynthetase syndrome.
- name: Inflammatory Myositis
category: Musculoskeletal
frequency: FREQUENT
description: >-
Inflammatory myopathy with symmetric proximal muscle weakness; may be absent or appear
later in the disease course (notably in ILD-predominant, non-Jo-1 patients). Prevalence
~73% in a 203-patient cohort.
phenotype_term:
preferred_term: Myopathy
term:
id: HP:0003198
label: Myopathy
evidence:
- reference: PMID:27594777
reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In a 2013 study of 203 anti-synthetase syndrome patients, the prevalence of ILD was
86%, more common than the prevalence of myositis (73%) or arthralgia/arthritis (60%)
explanation: >-
Supports the association and a frequent (30-79%) frequency band for myositis.
- name: Proximal Muscle Weakness
category: Musculoskeletal
description: >-
Symmetric proximal limb weakness reflecting the inflammatory myopathy component.
phenotype_term:
preferred_term: Proximal muscle weakness
term:
id: HP:0003701
label: Proximal muscle weakness
evidence:
- reference: PMID:27594777
reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
the prevalence of muscle symptoms (weakness and myalgia) was significantly lower in
patients with anti-PL7/PL12 as compared to those with anti-Jo1
explanation: >-
Supports muscle weakness as a manifestation of the syndrome (more frequent in
anti-Jo-1 disease).
- name: Inflammatory Arthritis
category: Musculoskeletal
frequency: FREQUENT
description: >-
Symmetric, usually non-erosive polyarthritis that can mimic rheumatoid arthritis;
arthralgia/arthritis prevalence ~60% in a 203-patient cohort.
phenotype_term:
preferred_term: Arthritis
term:
id: HP:0001369
label: Arthritis
evidence:
- reference: PMID:27594777
reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In a 2013 study of 203 anti-synthetase syndrome patients, the prevalence of ILD was
86%, more common than the prevalence of myositis (73%) or arthralgia/arthritis (60%)
explanation: >-
Supports the association and a frequent (30-79%) frequency band for arthralgia/arthritis.
- name: Mechanic's Hands
category: Integumentary
description: >-
Hyperkeratotic, fissured, scaling skin on the radial/ulnar surfaces of the fingers;
a characteristic but often subtle sign whose presence should prompt anti-synthetase
antibody testing.
phenotype_term:
preferred_term: Mechanic's hands (hyperkeratosis of the fingers)
term:
id: HP:0000962
label: Hyperkeratosis
evidence:
- reference: PMID:27594777
reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
the hyperkeratosis and scaling characteristic of mechanic’s hands are often subtle
findings whose presence should prompt further testing for anti-synthetase antibodies
explanation: >-
Supports mechanic's hands (finger hyperkeratosis/scaling) as a characteristic
cutaneous feature of the syndrome.
- name: Raynaud Phenomenon
category: Vascular
description: >-
Episodic digital vasospasm; a connective-tissue-disease-associated feature commonly
seen in antisynthetase syndrome.
phenotype_term:
preferred_term: Raynaud phenomenon
term:
id: HP:0030880
label: Raynaud phenomenon
evidence:
- reference: PMID:27594777
reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
clinical features that may include interstitial lung disease (ILD), non-erosive
arthritis, myositis, Raynaud’s phenomenon, unexplained fever and/or mechanic’s hands
explanation: >-
Supports Raynaud phenomenon as a recognized clinical feature of the syndrome.
- name: Unexplained Fever
category: Constitutional
description: >-
Unexplained fever, often accompanying disease flares, is part of the antisynthetase
constellation.
phenotype_term:
preferred_term: Fever
term:
id: HP:0001945
label: Fever
evidence:
- reference: PMID:27594777
reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
clinical features that may include interstitial lung disease (ILD), non-erosive
arthritis, myositis, Raynaud’s phenomenon, unexplained fever and/or mechanic’s hands
explanation: >-
Supports unexplained fever as a recognized clinical feature of the syndrome.
- name: Dyspnea
category: Respiratory
description: >-
Exertional breathlessness from interstitial lung disease, frequently the presenting
symptom in ILD-predominant disease.
phenotype_term:
preferred_term: Dyspnea
term:
id: HP:0002094
label: Dyspnea
evidence:
- reference: PMID:27594777
reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
decreased survival was seen in patients without muscle weakness and with severe dyspnea
explanation: >-
Supports dyspnea (from ILD) as a clinically important manifestation associated with
worse survival.
- name: Pulmonary Fibrosis
category: Respiratory
description: >-
Fibrotic progression of the interstitial lung disease (e.g., fibrotic NSIP or UIP
pattern), a leading cause of death.
phenotype_term:
preferred_term: Pulmonary fibrosis
term:
id: HP:0002206
label: Pulmonary fibrosis
clinical_course: PROGRESSIVE
evidence:
- reference: PMID:27594777
reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The most common causes of death were pulmonary fibrosis and pulmonary hypertension
explanation: >-
Supports pulmonary fibrosis as a fibrotic ILD outcome and a leading cause of death in
the syndrome.
- name: Pulmonary Arterial Hypertension
category: Cardiovascular
description: >-
A late complication associated with poor prognosis, secondary to chronic interstitial
lung disease and pulmonary vascular involvement.
phenotype_term:
preferred_term: Pulmonary arterial hypertension
term:
id: HP:0002092
label: Pulmonary arterial hypertension
evidence:
- reference: PMID:27594777
reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
disease-related sequelae that can include
progressive interstitial lung disease necessitating lung transplantation,
pulmonary hypertension, malignancy and decreased survival
explanation: >-
Supports pulmonary hypertension as a recognized disease-related sequela.
- name: Dysphagia
category: Gastrointestinal
description: >-
Swallowing difficulty from striated pharyngeal/esophageal muscle involvement in the
myositis component.
phenotype_term:
preferred_term: Dysphagia
term:
id: HP:0002015
label: Dysphagia
- name: Myalgia
category: Musculoskeletal
description: >-
Muscle pain accompanying the inflammatory myopathy.
phenotype_term:
preferred_term: Myalgia
term:
id: HP:0003326
label: Myalgia
evidence:
- reference: PMID:27594777
reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
the prevalence of muscle symptoms (weakness and myalgia) was significantly lower in
patients with anti-PL7/PL12 as compared to those with anti-Jo1
explanation: >-
Supports myalgia as a muscle symptom of the syndrome.
- name: Elevated Creatine Kinase
category: Laboratory
description: >-
Elevated serum creatine kinase reflecting myofiber injury; present when myositis is
active, but may be normal in amyopathic/ILD-predominant disease.
phenotype_term:
preferred_term: Elevated circulating creatine kinase concentration
term:
id: HP:0003236
label: Elevated circulating creatine kinase concentration
evidence:
- reference: PMID:27594777
reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
presence should prompt further testing for anti-synthetase antibodies and elevated
muscle enzymes
explanation: >-
Supports elevated muscle enzymes (creatine kinase) as a laboratory feature prompted by
the syndrome's findings.
biochemical:
- name: Anti-Jo-1 (Anti-Histidyl-tRNA Synthetase) Autoantibody
presence: Elevated
context: >-
The most common anti-aminoacyl-tRNA synthetase antibody; defines the classic, more
myositis-predominant phenotype. Antibody titer correlates with disease activity.
evidence:
- reference: PMID:28339994
reference_title: "A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
One hundred and twenty-four (73.4%) patients were positive for
anti-Jo1
explanation: >-
Supports anti-Jo-1 as the most frequent anti-synthetase antibody in an
antisynthetase-syndrome cohort.
- name: Anti-PL-7 / Anti-PL-12 (and other non-Jo-1 anti-ARS) Autoantibodies
presence: Elevated
context: >-
Non-Jo-1 anti-aminoacyl-tRNA synthetase antibodies (anti-PL-7/TARS1, anti-PL-12/AARS1,
anti-EJ/GARS1, anti-OJ/IARS1, anti-KS/NARS1) are associated with more lung-predominant,
often amyopathic disease.
evidence:
- reference: PMID:22771754
reference_title: "Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
ILD was more frequent (80% and 88% vs 67%, p=0.014)
whereas myositis was less common (44% and 47% vs 74%, p<0.001) in patients with
anti-PL7 and anti-PL12 compared to anti-Jo1
explanation: >-
Supports the lung-predominant, less-myopathic phenotype of anti-PL-7/anti-PL-12
versus anti-Jo-1.
- name: Anti-Ro52 (TRIM21) Co-Antibody
presence: Elevated
context: >-
Frequently co-positive with anti-synthetase antibodies and associated with worse
outcomes; in one cohort linked to earlier mechanic's hands, DM-specific skin findings,
and arthritis.
evidence:
- reference: PMID:28339994
reference_title: "A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Concurrent anti-Ro52 was more prevalent in anti-Jo1 patients
and was associated with earlier development of mechanic's hands, DM-specific
skin findings and arthritis
explanation: >-
Supports anti-Ro52 co-positivity as a phenotype-modifying serology.
genetic:
- name: HLA-DRB1 (8.1 ancestral haplotype) susceptibility
gene_term:
preferred_term: HLA-DRB1
term:
id: hgnc:4948
label: HLA-DRB1
association: Risk Factor
relationship_type: SUSCEPTIBILITY
notes: >-
MHC class II is the strongest susceptibility locus; HLA-DRB1*03:01 (and the linked 8.1
ancestral haplotype including HLA-B*08:01) is the principal predisposing marker,
particularly for anti-Jo-1, while HLA-DRB1*07:01 appears protective. This is a
susceptibility association, not a Mendelian causal mutation.
evidence:
- reference: PMID:33301929
reference_title: "HLA association with the susceptibility to anti-synthetase syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
A statistically significant increase of HLA-DRB1*03:01 and HLA-B*08:01
alleles in patients with ASSD compared to healthy controls was disclosed
explanation: >-
Directly supports HLA-DRB1*03:01 (and linked HLA-B*08:01 of the 8.1 haplotype) as a
susceptibility allele for antisynthetase syndrome.
- reference: PMID:33301929
reference_title: "HLA association with the susceptibility to anti-synthetase syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
a statistically significant increase of
HLA-DRB1*03:01 allele in anti-Jo-1 positive compared to anti-Jo-1 negative
patients with ASSD was observed
explanation: >-
Supports the particularly strong HLA-DRB1*03:01 association with anti-Jo-1-positive
disease.
- name: HARS1 (autoantigen; anti-Jo-1 target)
gene_term:
preferred_term: HARS1
term:
id: hgnc:4816
label: HARS1
association: Autoantigen
notes: >-
Histidyl-tRNA synthetase (HisRS) is the target of anti-Jo-1, the most common
anti-synthetase antibody. HARS1 is the autoantigen, not a mutated disease gene.
evidence:
- reference: PMID:36280495
reference_title: "Mechanistic perspectives on anti-aminoacyl-tRNA synthetase syndrome."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Antisynthetase syndrome (ASSD) is an autoimmune disease characterized by circulating
autoantibodies against one of eight aminoacyl-tRNA synthetases
explanation: >-
Supports this aminoacyl-tRNA synthetase as one of the eight aaRS autoantigen targets
defining the syndrome.
- name: TARS1 (autoantigen; anti-PL-7 target)
gene_term:
preferred_term: TARS1
term:
id: hgnc:11572
label: TARS1
association: Autoantigen
notes: Threonyl-tRNA synthetase; target of anti-PL-7. Autoantigen, not a causal mutation.
evidence:
- reference: PMID:36280495
reference_title: "Mechanistic perspectives on anti-aminoacyl-tRNA synthetase syndrome."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Antisynthetase syndrome (ASSD) is an autoimmune disease characterized by circulating
autoantibodies against one of eight aminoacyl-tRNA synthetases
explanation: >-
Supports this aminoacyl-tRNA synthetase as one of the eight aaRS autoantigen targets
defining the syndrome.
- name: AARS1 (autoantigen; anti-PL-12 target)
gene_term:
preferred_term: AARS1
term:
id: hgnc:20
label: AARS1
association: Autoantigen
notes: Alanyl-tRNA synthetase; target of anti-PL-12. Autoantigen, not a causal mutation.
evidence:
- reference: PMID:36280495
reference_title: "Mechanistic perspectives on anti-aminoacyl-tRNA synthetase syndrome."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Antisynthetase syndrome (ASSD) is an autoimmune disease characterized by circulating
autoantibodies against one of eight aminoacyl-tRNA synthetases
explanation: >-
Supports this aminoacyl-tRNA synthetase as one of the eight aaRS autoantigen targets
defining the syndrome.
- name: GARS1 (autoantigen; anti-EJ target)
gene_term:
preferred_term: GARS1
term:
id: hgnc:4162
label: GARS1
association: Autoantigen
notes: Glycyl-tRNA synthetase; target of anti-EJ. Autoantigen, not a causal mutation.
evidence:
- reference: PMID:36280495
reference_title: "Mechanistic perspectives on anti-aminoacyl-tRNA synthetase syndrome."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Antisynthetase syndrome (ASSD) is an autoimmune disease characterized by circulating
autoantibodies against one of eight aminoacyl-tRNA synthetases
explanation: >-
Supports this aminoacyl-tRNA synthetase as one of the eight aaRS autoantigen targets
defining the syndrome.
- name: IARS1 (autoantigen; anti-OJ target)
gene_term:
preferred_term: IARS1
term:
id: hgnc:5330
label: IARS1
association: Autoantigen
notes: Isoleucyl-tRNA synthetase; target of anti-OJ. Autoantigen, not a causal mutation.
evidence:
- reference: PMID:36280495
reference_title: "Mechanistic perspectives on anti-aminoacyl-tRNA synthetase syndrome."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Antisynthetase syndrome (ASSD) is an autoimmune disease characterized by circulating
autoantibodies against one of eight aminoacyl-tRNA synthetases
explanation: >-
Supports this aminoacyl-tRNA synthetase as one of the eight aaRS autoantigen targets
defining the syndrome.
- name: NARS1 (autoantigen; anti-KS target)
gene_term:
preferred_term: NARS1
term:
id: hgnc:7643
label: NARS1
association: Autoantigen
notes: Asparaginyl-tRNA synthetase; target of anti-KS. Autoantigen, not a causal mutation.
evidence:
- reference: PMID:36280495
reference_title: "Mechanistic perspectives on anti-aminoacyl-tRNA synthetase syndrome."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Antisynthetase syndrome (ASSD) is an autoimmune disease characterized by circulating
autoantibodies against one of eight aminoacyl-tRNA synthetases
explanation: >-
Supports this aminoacyl-tRNA synthetase as one of the eight aaRS autoantigen targets
defining the syndrome.
- name: TRIM21 (autoantigen; anti-Ro52 target)
gene_term:
preferred_term: TRIM21
term:
id: hgnc:11312
label: TRIM21
association: Autoantigen
notes: >-
Ro52/TRIM21 is the target of the anti-Ro52 co-antibody associated with worse outcome.
inheritance:
- name: Not Mendelian (multifactorial autoimmune)
description: >-
Antisynthetase syndrome is not inherited in a Mendelian fashion; it is a multifactorial,
polygenic autoimmune disease with HLA-driven susceptibility (e.g., HLA-DRB1*03:01).
Penetrance, expressivity, anticipation, and carrier-frequency concepts do not apply.
treatments:
- name: Corticosteroids
description: >-
First-line therapy for active muscle and/or lung disease. Corticosteroid monotherapy is
frequently insufficient (lung disease recurs with tapering), so adjunctive
immunosuppression is usually added.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: prednisone
term:
id: CHEBI:8382
label: prednisone
- preferred_term: prednisolone
term:
id: CHEBI:8378
label: prednisolone
target_mechanisms:
- target: Immune-Mediated Alveolar Injury and Interstitial Lung Disease
description: Broad anti-inflammatory/immunosuppressive control of the alveolar inflammation.
evidence:
- reference: PMID:27594777
reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Corticosteroids have long been first-line in the treatment of IIMs, though when
corticosteroids are used as monotherapy in anti-synthetase syndrome, there is frequent
lung disease recurrence with corticosteroid tapering
explanation: >-
Supports corticosteroids as first-line and the rationale for adding steroid-sparing
agents.
- name: Mycophenolate Mofetil
description: >-
A frequently used adjunctive steroid-sparing immunosuppressant; inhibits proliferating
lymphocytes by altering purine synthesis. Often combined with prednisone for ILD.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: mycophenolate mofetil
term:
id: CHEBI:8764
label: mycophenolate mofetil
target_mechanisms:
- target: Autoantibody and Cytotoxic Immune Effector Production
description: Suppresses proliferating lymphocytes driving the autoimmune effector response.
evidence:
- reference: PMID:27594777
reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Frequently used adjunctive agents include
azathioprine, mycophenolate mofetil, tacrolimus, rituximab, and cyclophosphamide
explanation: >-
Supports mycophenolate mofetil as a frequently used adjunctive immunosuppressant.
- name: Azathioprine
description: >-
Adjunctive steroid-sparing immunosuppressant; halts purine synthesis. Most frequently
used as maintenance therapy in conjunction with prednisone. TPMT/NUDT15 status affects
myelosuppression risk.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: azathioprine
term:
id: CHEBI:2948
label: azathioprine
evidence:
- reference: PMID:27594777
reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
azathioprine has been most frequently used as maintenance therapy often in conjunction
with prednisone
explanation: >-
Supports azathioprine as a maintenance steroid-sparing agent.
- name: Tacrolimus
description: >-
Calcineurin inhibitor used as add-on therapy, particularly for more severe ILD; case
series in antisynthetase-syndrome-ILD show improved lung function and reduced
corticosteroid dose.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: tacrolimus
term:
id: CHEBI:61049
label: tacrolimus (anhydrous)
target_mechanisms:
- target: Autoantibody and Cytotoxic Immune Effector Production
description: Calcineurin inhibition suppresses T-cell-driven autoimmune effector activity.
evidence:
- reference: PMID:27594777
reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
A 2005 case series specifically studied tacrolimus efficacy in 15 patients with
anti-synthetase syndrome-ILD. Most of these patients had Jo-1 autoantibodies, and
experienced improvement in lung function and muscle symptoms
explanation: >-
Supports tacrolimus as an effective add-on for antisynthetase-syndrome-ILD.
- name: Rituximab
description: >-
Anti-CD20 monoclonal antibody depleting B cells; used for severe, progressive, or
refractory ILD ("rescue therapy"), with case series showing FVC improvement.
therapeutic_modality: MONOCLONAL_ANTIBODY
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: rituximab
term:
id: NCIT:C1702
label: Rituximab
target_mechanisms:
- target: Autoantibody and Cytotoxic Immune Effector Production
description: B-cell depletion reduces autoantibody-producing plasma-cell precursors.
evidence:
- reference: PMID:27594777
reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In the setting of anti-synthetase syndrome, we use rituximab for patients with severe
progressive and/or refractory ILD
explanation: >-
Supports rituximab for severe progressive/refractory antisynthetase-syndrome ILD.
- name: Cyclophosphamide
description: >-
Cytotoxic alkylating agent reserved for severe IIM-ILD, particularly acute
respiratory distress syndrome / rapidly progressive ILD, given its toxicity profile.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: cyclophosphamide
term:
id: CHEBI:4027
label: cyclophosphamide
evidence:
- reference: PMID:27594777
reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
have used cyclophosphamide in ARDS
explanation: >-
Supports cyclophosphamide reserved for severe/ARDS-like antisynthetase-syndrome ILD.
- name: Intravenous Immunoglobulin (IVIG)
description: >-
Pooled donor IgG used as adjunctive therapy, especially for refractory myositis; a case
report suggests possible benefit in IIM-related ILD.
therapeutic_modality: OTHER
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
evidence:
- reference: PMID:27594777
reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Intravenous immunoglobulin (IVIG), a blood product containing the pooled immunoglobulin
G antibodies from donors, is used in the treatment of many immune deficiency and
autoimmune disorders
explanation: >-
Supports IVIG as an adjunctive immunomodulatory therapy used in autoimmune disease.
- name: Lung Transplantation
description: >-
Reserved for end-stage progressive interstitial lung disease refractory to medical
therapy.
treatment_term:
preferred_term: organ transplantation
term:
id: MAXO:0010039
label: organ transplantation
evidence:
- reference: PMID:27594777
reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
progressive interstitial lung disease necessitating lung transplantation
explanation: >-
Supports lung transplantation for end-stage progressive ILD.
diagnosis:
- name: Anti-Aminoacyl-tRNA Synthetase Antibody Testing
description: >-
The serological cornerstone of diagnosis. Diagnostic criteria (Connors 2010; Solomon
2011) require an anti-tRNA-synthetase autoantibody plus one or more compatible clinical
features (mechanic's hands, Raynaud, myositis, ILD, arthritis, unexplained fever).
evidence:
- reference: PMID:27594777
reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
These criteria proposed that all patients with anti-synthetase syndrome must have
evidence for a tRNA synthetase autoantibody, in addition to one or more of the
following clinical features: mechanic’s hands, Raynaud’s phenomenon, myositis, ILD,
arthritis, and/or unexplained fever
explanation: >-
Supports anti-synthetase antibody plus a compatible clinical feature as the diagnostic
basis.
- name: High-Resolution Chest CT and Pulmonary Function Testing
description: >-
HRCT characterizes the ILD pattern (NSIP/OP/UIP); pulmonary function tests with DLCO
assess restriction and diffusion and are used for serial monitoring.
evidence:
- reference: PMID:27594777
reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Diagnosis is made by a multidisciplinary
approach, synthesizing rheumatology and pulmonary evaluations, along with
serologic, radiographic, and occasionally muscle and/or lung biopsy results
explanation: >-
Supports the multidisciplinary, serologic/radiographic/biopsy-based diagnostic workup.
differential_diagnoses:
- name: Polymyositis and Dermatomyositis
description: >-
Other idiopathic inflammatory myopathies with which antisynthetase syndrome overlaps;
historically these patients were diagnosed as PM or DM.
distinguishing_features:
- >-
Antisynthetase syndrome is defined by anti-aminoacyl-tRNA synthetase antibodies and has
a higher prevalence and severity of ILD than DM/PM.
- >-
It lacks the defining DM skin signs (heliotrope rash, Gottron papules) unless in overlap.
- >-
Muscle biopsy shows perimysial fragmentation/perifascicular necrosis distinct from DM
perifascicular atrophy and PM endomysial CD8 invasion.
evidence:
- reference: PMID:27594777
reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
There is a higher prevalence and increased severity
of interstitial lung disease in patients with anti-synthetase syndrome, as
compared to dermatomyositis and polymyositis
explanation: >-
Supports the ILD-predominance distinction from DM/PM.
- name: Idiopathic Interstitial Pneumonia (e.g., IPF / idiopathic NSIP)
description: >-
Antisynthetase-syndrome ILD can present as apparently idiopathic interstitial pneumonia
before the autoimmune basis is recognized.
distinguishing_features:
- >-
A myositis-antibody panel reveals an anti-synthetase antibody; in one retrospective
analysis of 198 idiopathic interstitial pneumonia patients, 13 were later found to have
an anti-synthetase antibody.
evidence:
- reference: PMID:27594777
reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
in a recent retrospective analysis of 198 patients with idiopathic interstitial
pneumonia, 13 patients were later noted to have an anti-synthetase antibody
explanation: >-
Supports the need to differentiate antisynthetase ILD from idiopathic interstitial
pneumonia by antibody testing.
epidemiology:
- name: Incidence and Prevalence
description: >-
A rare disease. In a US population-based cohort (Olmsted County, Minnesota, 1998-2019),
the age- and sex-adjusted incidence was 0.56 per 100,000 and point prevalence 9.21 per
100,000. No significant increase in malignancy risk was observed in this and another
cohort.
evidence:
- reference: PMID:39814448
reference_title: "Epidemiology of Antisynthetase Syndrome and Risk of Malignancy in a Population-Based Cohort (1998-2019)."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The age- and sex-adjusted
incidence of ASS was 0.56 (95% CI 0.25-0.87) per 100,000 population.
explanation: Supports the population-based incidence estimate.
- reference: PMID:28339994
reference_title: "A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
There was no
significant increase in mortality or cancer risk in ASyS patients compared with
the general US population.
explanation: >-
Supports the comparatively low malignancy/mortality risk relative to classic
dermatomyositis.
progression:
- phase: Accrual of Manifestations and ILD-Driven Course
notes: >-
Adult-onset (peak 5th-6th decade), subacute-to-chronic and insidious; manifestations
accrue over time from "incomplete" to "complete" syndrome. Course is chronic and
relapsing, with ILD severity (especially fibrotic progression) determining prognosis.
Phenotype and survival correlate with anti-ARS antibody specificity (worse with
anti-PL-7/PL-12 than anti-Jo-1).
evidence:
- reference: PMID:22771754
reference_title: "Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In patients with ASS, the phenotype and the
survival were correlated with the anti-ARS specificity.
explanation: >-
Supports antibody-specificity-dependent phenotype and survival.
classifications:
harrisons_chapter:
- classification_value: IMMUNE_RHEUMATOLOGIC
evidence:
- reference: PMID:27594777
reference_title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Anti-synthetase syndrome is an autoimmune condition, characterized by antibodies
directed against an aminoacycl transfer RNA synthetase
explanation: >-
Supports classification as a systemic autoimmune/rheumatologic disease.
references:
- reference: PMID:36280495
title: "Mechanistic perspectives on anti-aminoacyl-tRNA synthetase syndrome."
findings: []
- reference: PMID:27594777
title: "The Diagnosis and Treatment of Antisynthetase Syndrome."
findings: []
- reference: PMID:39814448
title: "Epidemiology of Antisynthetase Syndrome and Risk of Malignancy in a Population-Based Cohort (1998-2019)."
findings: []
- reference: PMID:22771754
title: "Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity."
findings: []
- reference: PMID:28339994
title: "A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies."
findings: []
Overview. Antisynthetase syndrome (ASSD / ASyS / ASS) is a systemic autoimmune disease, a distinct subset of the idiopathic inflammatory myopathies (IIM), defined serologically by circulating autoantibodies directed against one of the cytoplasmic aminoacyl-tRNA synthetases (aaRS). It is clinically dominated by a triad of interstitial lung disease (ILD), inflammatory myositis, and inflammatory (usually non-erosive) arthritis, frequently accompanied by the "ancillary" features mechanic's hands, Raynaud phenomenon, and unexplained fever. ILD is the chief driver of morbidity and mortality and often predominates at presentation, so the disorder is genuinely a multisystem connective-tissue disease rather than "just a myopathy."
"Antisynthetase syndrome is characterized by symptoms of muscle weakness, arthritis, mechanic's hands, interstitial lung disease (ILD), Raynaud phenomenon, and a positive anti–tRNA-synthetase antibody." [search-derived]
Key identifiers:
- MONDO: MONDO:0019344 — antisynthetase syndrome [verified via local OAK]
- Orphanet: ORPHA:81 (Antisynthetase syndrome)
- OMIM: No single Mendelian OMIM entry (complex/polygenic autoimmune disease — not a monogenic disorder)
- ICD-10: No dedicated code; typically captured under M35.8 (other specified systemic involvement of connective tissue) or the myositis/ILD codes (e.g., M33.x dermatomyositis/polymyositis; J84.x for the ILD component)
- ICD-11: 4A41 region (overlap/undifferentiated connective tissue diseases / inflammatory myopathies); no unique stem code
- MeSH: No standalone MeSH descriptor; indexed via "Myositis," "Lung Diseases, Interstitial," and the supplementary concept for aminoacyl-tRNA synthetase autoantibodies
Data derivation: Disease-level aggregated resources (review syntheses, multicenter cohorts such as AENEAS, registry/population studies). A small amount is EHR/population-based (e.g., the Olmsted County population cohort, PMID 39814448).
Synonyms / alternative names: Anti-synthetase syndrome; anti-aminoacyl-tRNA synthetase syndrome; anti-ARS syndrome; ASyS; ASSD; Jo-1 syndrome (when anti-Jo-1 positive — a partial synonym); "antisynthetase syndrome–associated ILD (ASS-ILD)" for the pulmonary-predominant phenotype.
Causal factors. ASSD is a multifactorial autoimmune disease — there is no single causal gene or pathogen. It arises from a loss of immune tolerance to one or more aaRS enzymes in a genetically susceptible host, likely triggered or amplified by environmental/mucosal (especially pulmonary) exposures. The serological hallmark — an anti-aaRS antibody whose titer tracks disease activity — implies the autoantibody response is mechanistically central rather than a bystander.
"titers of the serum anti-Jo-1 antibodies correlate with disease activity" — Kanaji et al., Trends Biochem Sci (PMID 36280495) [verified]
Genetic risk factors (susceptibility loci — not Mendelian causes): - MHC class II is the strongest risk locus. In Caucasian patients, HLA-DRB1*03:01 and the linked HLA-B*08:01, HLA-DQA1*05:01, and HLA-DQB1*02:01 alleles (the ancestral 8.1 haplotype) are the principal predisposing markers, particularly for anti-Jo-1. HLA-DRB1*07:01 appears protective. [search-derived] - In Korean/Japanese populations, anti-ARS associates with HLA-DRB1*08:03 (an example of population-specific HLA risk). [search-derived] - Non-HLA candidate: single-nucleotide variants in IL1B influencing IL-1β serum levels have been reported as susceptibility factors (PMC7732678). [search-derived]
Environmental / lifestyle risk factors: - Sex: female predominance (≈2–3:1 female:male). - Smoking: associated with increased risk of anti-Jo-1 positivity specifically in HLA-DRB1*03–positive individuals — a candidate gene–environment interaction. - Age: peak onset in the 5th–6th decades.
Gene–environment interaction (mechanistic hypothesis): the interaction between HLA-DRB1*03 and cigarette smoke is hypothesized to promote anti-Jo-1 generation — analogous to the smoking × shared-epitope model in rheumatoid arthritis, with the lung as the site of tolerance breakdown (post-translational modification/neoantigen exposure of HisRS in inflamed lung). [search-derived]
Protective factors: HLA-DRB1*07:01 (genetic, above). No well-established environmental protective factor.
ASSD presents as "complete" (full triad) or, more commonly, "incomplete" forms; manifestations accrue over time, so the picture evolves. Approximate frequencies vary widely by cohort and by antibody (see §9). The figures below are pooled from the diagnosis/treatment review (PMID 27594777) [verified] and standard reviews.
| Phenotype | Type | Approx. frequency | Suggested HPO term |
|---|---|---|---|
| Interstitial lung disease (NSIP > OP > UIP patterns; dyspnea, dry cough) | Clinical/imaging | 70–90% (86% in one 203-pt cohort) | HP:0006530 Abnormal pulmonary interstitial morphology |
| Inflammatory myositis / proximal muscle weakness | Sign | ~60–75% | HP:0003701 Proximal muscle weakness; HP:0003198 Myopathy |
| Inflammatory arthritis / arthralgia (symmetric, non-erosive, often RA-mimicking) | Sign | ~50–60% | HP:0001369 Arthritis; HP:0002829 Arthralgia |
| Mechanic's hands (hyperkeratotic, fissured, scaling skin of radial/ulnar fingers) | Physical sign | ~30% | HP:0010765 Palmar hyperkeratosis (closest; "mechanic's hands" lacks a precise HPO term — verify) |
| Raynaud phenomenon | Symptom | ~40% | HP:0030880 Abnormal vascular physiology / HP:0033740? → use HP:0030880-family; commonly mapped to Raynaud phenomenon — verify term |
| Fever (unexplained, often at flares) | Symptom | ~20% | HP:0001945 Fever |
| Dyspnea | Symptom | common | HP:0002094 Dyspnea |
| Elevated creatine kinase | Lab abnormality | common when myositis present | HP:0003236 Elevated circulating creatine kinase concentration |
| Dysphagia (esophageal/pharyngeal muscle) | Symptom | subset | HP:0002015 Dysphagia |
| Pulmonary fibrosis (late) | Imaging/path | subset, prognostic | HP:0002206 Pulmonary fibrosis |
| Pulmonary arterial hypertension (late complication) | Sign | subset, poor prognosis | HP:0002092 Pulmonary arterial hypertension |
| Myalgia | Symptom | common | HP:0003326 Myalgia |
Phenotype characteristics: Adult-onset (mean 43–60 yr; see §9). Onset is subacute-to-chronic and insidious; course is typically chronic, relapsing, and frequently progressive in the lung. Severity is highly variable — from clinically amyopathic/ILD-only (often non-Jo-1 antibodies) to fulminant myositis or rapidly progressive ILD. Mechanic's hands and Raynaud are markers of the syndrome but rarely disabling; ILD severity drives prognosis.
Quality-of-life impact: Dominated by the ILD (exertional dyspnea, oxygen dependence, reduced exercise capacity) and by myositis-related functional limitation (climbing, lifting, swallowing). Arthritis adds RA-like functional impairment. No ASSD-specific PRO instrument; SF-36/EQ-5D and myositis tools (e.g., HAQ, Myositis Activities Profile) are used generically.
This is not a Mendelian disease — there are no causal germline mutations. The "molecular genetics" are HLA susceptibility (see §2): HLA-DRB1*03:01, HLA-B*08:01, DQA1*05:01, DQB1*02:01 (8.1 haplotype) confer risk; DRB1*07:01 protective; DRB1*08:03 in East Asians. HGNC anchors for the relevant loci: HGNC:4948 HLA-DRB1, HGNC:4932 HLA-B, HGNC:4942 HLA-DQA1, HGNC:4944 HLA-DQB1; HGNC:5992 IL1B (candidate modifier).
Autoantigen genes (the targets of the autoantibodies, not mutated genes): the eight aaRS genes — HGNC:4815 HARS1 (HisRS / Jo-1), HGNC:11572 TARS1 (ThrRS / PL-7), HGNC:348 AARS1 (AlaRS / PL-12), HGNC:6053 IARS1 (IleRS / OJ), HGNC:4162 GARS1 (GlyRS / EJ), HGNC:751 NARS1 (AsnRS / KS), HGNC:3650 FARSB (PheRS / Zo), HGNC:6512 KARS1 (LysRS / SC/Ha).
No somatic variants, no chromosomal abnormalities, no established disease-specific epigenetic signature define ASSD. The molecular pathology is autoantibody- and immune-mediated, not genomic. Functional consequence of the autoimmunity is loss-of-tolerance and immune-complex formation (see §6), not loss/gain of aaRS enzymatic function.
Modifier serologies (act like molecular modifiers of phenotype): anti-Ro52/TRIM21 co-positivity (up to ~50% of patients) associates with more ILD and worse pulmonary outcome. HGNC:11312 TRIM21.
The current model is a self-amplifying innate-plus-adaptive autoimmune loop centered on aaRS autoantigens, with the lung and muscle as the principal sites. Cited details are from Kanaji et al. (PMID 36280495) [verified] unless noted.
Causal chain (upstream → downstream):
Tissue injury / regeneration + tissue-specific aaRS secretion (upstream trigger). Damaged or regenerating muscle (and inflamed lung) upregulate MHC class I on myofibers and secrete certain aaRSs. IGF-1–stimulated human skeletal muscle cells selectively secrete HisRS (not MetRS), and most ASSD-linked aaRSs appear in the secretome/exosomes of differentiating myoblasts and virus-infected macrophages — implicating extracellular mobility as a key determinant of which aaRS becomes an autoantigen (~85% of patients target a class IIa aaRS not bound in the multisynthetase complex).
"most aaRSs detected from the secretome/exosome of human differentiating myoblasts and virus-infected primary macrophages are associated with ASSD."
Neoepitope exposure — the WHEP domain. HisRS (Jo-1) is the dominant target (30–60%). The immunodominant epitope is the WHEP domain — a small (~50-aa) helix-turn-helix motif outside the catalytic core that is "highly exposed and flexible, often disordered." A lung-enriched HisRS splice variant (aa 1–60) and a granzyme-B cleavage fragment (HisRS1-48) expose this domain extracellularly, linking cytotoxic muscle/lung injury to autoantigen generation.
Antigen presentation & T-cell help. Dendritic cells take up secreted aaRS and present peptides on MHC class II (HLA-DR) to aaRS-specific CD4+ T cells, driving B-cell help and class-switched autoantibody production.
Immune-complex formation + TLR-driven interferon (the amplification loop). Anti-Jo-1 binds HisRS together with HisRS-bound tRNA/tRNA fragments, forming immune complexes. Via Fcγ receptors, complexes are internalized into endosomes where the nucleic-acid cargo triggers TLR7/8, releasing type I interferon and proinflammatory cytokines — a positive feedback loop that perpetuates autoantibody production. A 5′-half tRNA-His fragment released in extracellular vesicles can activate endosomal TLR7.
"the HisRS/tRNA complex is internalized to the endosome, where the tRNA triggers TLR7/8 signaling and interferon release."
Interferon programs (effector arm). ASSD muscle shows type II IFN–inducible genes (e.g., PSMB8) and MHC-II/HLA-DR upregulation on myofibers; type I IFN drives autoantibody persistence and MHC class I overexpression. In ASS-ILD, monocyte-driven IFN and TNF programs orchestrate the inflammatory network (Frontiers Immunol 2025, PMC12589074). [search-derived]
Neutrophils / NETs (tissue-damage effector). Myositis-specific antibodies promote NET formation with impaired NET degradation, contributing to injury in lung, muscle, and vessels — a proposed driver of the fibrotic ILD (parallels RA-ILD NET biology). [search-derived]
Chemokine activity of the autoantigen. The HisRS WHEP domain has intrinsic chemokine-like activity (activates chemokine receptors on T cells and immature dendritic cells), recruiting immune cells to tissues expressing/secreting it — a built-in feed-forward to sites like muscle and lung.
Downstream tissue damage → clinical disease. The net result is interstitial lung inflammation/fibrosis, myofiber injury (perimysial/perifascicular, with MHC-I upregulation), synovitis, and vasculopathy (Raynaud, mechanic's hands).
Ontology suggestions:
- GO (biological processes): GO:0002377 immunoglobulin production; GO:0019882 antigen processing and presentation; GO:0002224 toll-like receptor signaling pathway; GO:0032606 type I interferon production; GO:0032609 type II interferon production / GO:0034341 response to type II interferon; GO:0006954 inflammatory response; GO:0140447 cytokine production involved in inflammatory response; (NET formation: GO:0140148-family — verify a current NETosis GO ID); GO:0004812 aminoacyl-tRNA ligase activity (autoantigen's native function).
- CL (cell types): CL:0000576 monocyte; CL:0000775 neutrophil; CL:0000451 dendritic cell; CL:0000624 CD4-positive T cell; CL:0000236 B cell; CL:0000786 plasma cell; CL:0002063 type II pneumocyte; CL:0000057 fibroblast; CL:0000187 muscle cell / CL:0000188 skeletal muscle cell.
- GO cellular component (subcellular): GO:0005768 endosome (TLR signaling site); GO:0005737 cytoplasm (aaRS native compartment).
Organ level (primary):
- Lung (UBERON:0002048) — interstitium; ILD is the dominant organ injury. Patterns: NSIP (most common), organizing pneumonia, UIP, sometimes diffuse alveolar damage.
- Skeletal muscle (UBERON:0001134; muscle organ UBERON:0002385) — inflammatory myopathy, perimysial/perifascicular distribution.
- Joints / synovium (UBERON:0002217 synovial joint; UBERON:0002484 synovial membrane) — inflammatory arthritis.
Secondary / additional involvement:
- Skin (UBERON:0002097) — mechanic's hands; sometimes DM-like rash (Gottron, heliotrope) in overlap.
- Peripheral vasculature / digital vessels — Raynaud phenomenon.
- Esophagus (UBERON:0001043) — dysphagia from striated-muscle involvement.
- Heart (UBERON:0000948) — under-recognized myocarditis and pulmonary hypertension/right-heart strain (late). [search-derived: anti-Jo-1 myocarditis reports]
Body systems: respiratory, musculoskeletal, integumentary, cardiovascular, immune.
Tissue/cell level: alveolar epithelium (type II pneumocytes), pulmonary interstitial fibroblasts/myofibroblasts; skeletal myofibers; synovial lining; recruited monocytes, neutrophils, T and B cells.
Localization / lateralization: ILD is bilateral, typically basal/peripheral predominant. Myositis is proximal and symmetric. Arthritis is symmetric/polyarticular. Mechanic's hands are bilateral on radial/ulnar finger surfaces.
Epidemiology: - Incidence: age-/sex-adjusted ~0.56 per 100,000/year (95% CI 0.25–0.87) in a US population-based cohort (Olmsted County, 1998–2019; PMID 39814448). [search-derived] - Prevalence: rare; not precisely established. Orphanet lists it as a rare disease. - Sex ratio: female-predominant, ~2–3:1 (some myositis-predominant cohorts skew more female). - Age distribution: adult, peak 5th–6th decade.
Inheritance: Not inherited in a Mendelian fashion — multifactorial/polygenic with HLA-driven susceptibility. No penetrance/expressivity/anticipation/mosaicism/carrier-frequency concepts apply. Founder/population effects appear only at the level of population-specific HLA risk alleles (DRB1*03:01 in Europeans; DRB1*08:03 in East Asians). Consanguinity is not relevant.
Antibody distribution (defines serologic subgroups): - Anti-Jo-1 (HARS1): most common — ~20–30% of all IIM; ~70–88% of antisynthetase patients (72% in AENEAS, n=828). Phenotype: classic triad, more myositis. - Anti-PL-7 (TARS1): ~18% of anti-ARS (Japanese cohort). - Anti-PL-12 (AARS1): ~11%; ILD-predominant, often amyopathic, less muscle. - Anti-EJ (GARS1): ~23% (Japanese); myositis-associated. - Anti-OJ (IARS1): ~5%; ILD-predominant. - Anti-KS (NARS1): ~8%; ILD-predominant, minimal myositis. - Anti-Zo (FARSB) and anti-Ha/SC (KARS1): rare.
"Myositis was closely associated with anti-Jo-1, anti-EJ, and anti-PL-7, while interstitial lung disease (ILD) was correlated with all 6 anti-ARS antibodies." [search-derived]
Co-antibody: anti-Ro52/TRIM21 in up to ~50% — marks more severe ILD.
Geographic distribution: Worldwide; no strong endemicity. Subtype distribution shifts by ancestry (e.g., higher anti-EJ in Japanese cohorts).
Diagnosis = anti-aaRS antibody + ≥1 compatible clinical feature (per Connors); Solomon criteria are stricter. Connors/Lega criteria are more sensitive; specificities are comparable. [verified PMID 27594777 + search-derived]
Serology (cornerstone): - Myositis line/immunoblot panels detecting the 8 anti-aaRS (anti-Jo-1, PL-7, PL-12, EJ, OJ, KS, Zo, Ha). Immunoprecipitation remains a reference method (best for anti-OJ, which line blots miss). Anti-Ro52 should be tested concurrently. - Caveat: patients can be antibody-positive yet "seronegative" by limited panels (anti-OJ, anti-KS frequently missed) — clinical suspicion matters.
Laboratory:
- Creatine kinase (LOINC:2157-6) and aldolase — elevated with active myositis (may be normal in amyopathic/ILD-predominant disease).
- ANA (often negative or low-titer cytoplasmic pattern — a clue), aldolase, LDH, AST/ALT.
Imaging: - HRCT chest — NSIP/OP/UIP patterns; the key ILD test. - Muscle MRI — edema/inflammation, guides biopsy.
Functional / electrophysiology: - Pulmonary function tests (PFTs) with DLCO — restrictive pattern, reduced diffusion; monitored every 2–3 months until remission. - EMG — irritable myopathy.
Biopsy / pathology: - Muscle biopsy — characteristic perimysial fragmentation, perifascicular necrosis, MHC-I sarcolemmal upregulation (distinct from DM's perifascicular atrophy and PM's endomysial pattern). - Lung biopsy — rarely needed; cellular/fibrotic NSIP, OP.
Genetic testing: Not used diagnostically (no Mendelian basis). HLA typing is research/risk-stratification only. WGS/WES/panels/karyotype/CMA/FISH/mtDNA/repeat testing are not applicable.
Omics-based diagnostics: Investigational — peripheral-blood IFN signatures, monocyte transcriptomics (ASS-ILD), and autoantibody profiling are research tools, not validated clinical diagnostics.
Clinical criteria: Connors (2010), Solomon (2011), Lega; ACR/EULAR IIM criteria capture the myositis component but not ILD-predominant ASSD.
Differential diagnosis: Other IIM (DM, PM, IMNM, IBM); idiopathic pulmonary fibrosis / idiopathic NSIP; rheumatoid arthritis (ASSD arthritis is RA-mimicking, can be anti-CCP–negative → "seronegative RA" reclassified as ASSD); systemic sclerosis/MCTD; hypersensitivity pneumonitis; Sjögren-ILD.
Screening: No population screening. In a patient with unexplained ILD, myositis antibody panel is the key targeted "screen."
No randomized controlled trials exist — management is consensus/expert-based. (MAXO:0000058-family immunosuppressive therapy; NCIT:C15986 Pharmacotherapy as the action term.)
First line:
- Glucocorticoids (prednisone/prednisolone), medium-to-high dose — CHEBI:8382 prednisone / CHEBI:8378 prednisolone; agent class NCIT:C2322 Corticosteroid. (MAXO:0000058? prefer NCIT:C15986 + corticosteroid agent.)
- Steroid-sparing immunosuppressant added early — mycophenolate mofetil (CHEBI:8764), azathioprine (CHEBI:2948), or tacrolimus (CHEBI:61049) as add-on.
"prednisone AND mycophenolate mofetil or azathioprine; consider tacrolimus as add-on therapy" — PMID 27594777 [verified]
Refractory / progressive ILD:
- Rituximab (anti-CD20 mAb; rescue therapy; PFT improvement at ~6 months) — agent NCIT:C2480 Rituximab; modality MONOCLONAL_ANTIBODY.
- Cyclophosphamide (CHEBI:4026) for severe/rapidly progressive ILD or ARDS-like presentation.
- IVIG — adjunct, especially for refractory myositis/dysphagia.
- Combination MMF + rituximab reported beneficial in refractory IIM. [search-derived]
Antifibrotic (emerging): Nintedanib (CHEBI:85164) for progressive fibrosing ILD phenotypes (extrapolated from INBUILD/progressive-pulmonary-fibrosis data) — investigational/adjunct in ASS-ILD.
Targeted/experimental: JAK inhibitors (targeting the IFN axis) and other biologics are under study; numerous trials for myositis-ILD on ClinicalTrials.gov (search for active NCTs before listing).
Supportive / rehabilitative: supplemental oxygen, pulmonary rehabilitation, physical/occupational therapy (MAXO:0000011 physical therapy), aspiration precautions for dysphagia, vaccination/PJP prophylaxis under immunosuppression, lung transplantation for end-stage ILD (MAXO:0010039 organ transplantation).
Pharmacogenomics: TPMT/NUDT15 genotyping before azathioprine (myelosuppression risk) — standard CPIC guidance; the one genotype-guided step relevant to ASSD therapy.
Monitoring: PFTs/DLCO every 2–3 months until remission; CK and muscle strength for myositis; HRCT for ILD progression.
NCBITaxon:9606 (Homo sapiens).NCBI Gene mouse ortholog), etc. — but conservation of the enzyme does not imply conservation of the disease.ASSD is difficult to model; no single model recapitulates the full human triad.
MONDO:0019344 antisynthetase syndrome.HP:0006530 (ILD), HP:0003701 (proximal weakness), HP:0003198 (myopathy), HP:0001369 (arthritis), HP:0002829 (arthralgia), HP:0010765 (palmar hyperkeratosis ≈ mechanic's hands — verify), Raynaud (verify term), HP:0001945 (fever), HP:0002094 (dyspnea), HP:0003236 (elevated CK), HP:0002015 (dysphagia), HP:0002206 (pulmonary fibrosis), HP:0002092 (PAH).GO:0002377, GO:0019882, GO:0002224, GO:0032606, GO:0034341, GO:0006954, GO:0004812.CL:0000576, CL:0000775, CL:0000451, CL:0000624, CL:0000236, CL:0000786, CL:0002063, CL:0000057, CL:0000188.UBERON:0002048 (lung), UBERON:0001134 (skeletal muscle tissue), UBERON:0002217 (synovial joint), UBERON:0002097 (skin), UBERON:0001043 (esophagus).CHEBI:8382 prednisone, CHEBI:8764 mycophenolate mofetil, CHEBI:2948 azathioprine, CHEBI:61049 tacrolimus, CHEBI:4026 cyclophosphamide, CHEBI:85164 nintedanib.NCIT:C15986 Pharmacotherapy (+ agents); MAXO:0000011 physical therapy; MAXO:0010039 organ transplantation; MAXO:0000950 supportive care.| PMID / ID | What it supports | Status |
|---|---|---|
| 36280495 — Kanaji et al., Trends Biochem Sci 2022/2023, "Mechanistic perspectives on anti-aminoacyl-tRNA synthetase syndrome" | Full pathophysiology: aaRS autoantigens, WHEP domain, TLR7/8–IFN loop, secretome, chemokine activity | [verified] |
| 27594777 — "The Diagnosis and Treatment of Antisynthetase Syndrome" (PMC5006392) | Criteria, frequencies, the 8 antibodies, prognosis/survival, treatment algorithm | [verified] |
| 39814448 — Epidemiology of ASS & malignancy, population-based cohort 1998–2019, J Rheumatol | Incidence 0.56/100,000; malignancy risk | search-derived |
| PMC11050089 / MDPI IJMS 2024 — Review of ASS-associated ILD | ILD patterns, NETs, pathogenesis | search-derived |
| PMC12589074 — Monocyte-driven IFN/TNF programs in ASS-ILD (Front Immunol 2025) | Monocyte IFN signature | search-derived |
| PMC11137886 / PMC10362709 — Anti-Jo-1 antibody levels & prognosis | Antibody titer as activity biomarker | search-derived |
| AENEAS cohort (Cavagna et al.; n=828) | Antibody distribution (Jo-1 72%), clinical time course | search-derived — locate PMID |
| Anti-Ro52 cohort (Clin Exp Rheumatol) | Ro52 ~50%, worse ILD | search-derived |
Sources (URLs): - https://pmc.ncbi.nlm.nih.gov/articles/PMC9974581/ (mechanism review, PMID 36280495) - https://pmc.ncbi.nlm.nih.gov/articles/PMC5006392/ (diagnosis/treatment, PMID 27594777) - https://pmc.ncbi.nlm.nih.gov/articles/PMC9136399/ (aaRS: on anti-synthetase syndrome and beyond) - https://pmc.ncbi.nlm.nih.gov/articles/PMC11050089/ (ASS-ILD review) - https://pubmed.ncbi.nlm.nih.gov/39814448/ (population epidemiology) - https://pmc.ncbi.nlm.nih.gov/articles/PMC11137886/ (anti-Jo-1 levels & prognosis) - https://pmc.ncbi.nlm.nih.gov/articles/PMC6222225/ (HLA/genetics, Hungarian cohort) - https://pmc.ncbi.nlm.nih.gov/articles/PMC7732678/ (IL1B susceptibility) - https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1652999/full (monocyte IFN/TNF in ASS-ILD) - https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=GB&Expert=81 (Orphanet ORPHA:81) - https://rarediseases.org/rare-diseases/antisynthetase-syndrome/ (NORD overview)
A kb/disorders/Antisynthetase_Syndrome.yaml entry already exists on this branch (MONDO:0019344, with pathophysiology and phenotype scaffolding). This report is structured to fill it out — prioritize: (1) the verified mechanism chain from PMID 36280495 (autoantigen secretion → WHEP epitope → immune complex → TLR7/8 → IFN loop → tissue damage); (2) antibody-subtype phenotype heterogeneity (§9); (3) the ILD-centric prognosis/treatment (§§11–12). Before any snippet becomes an evidence: item, run just fetch-reference PMID:XXXX then confirm the quote is an exact substring of the cached abstract — especially for every claim I flagged [search-derived], and watch for the mechanic's-hands and Raynaud HPO terms, which need OAK verification (the ontology may lack precise matches).